News

CEO Anders Weilandt presents Chordate Medical at Investment event on June 9th

23 May, 2022

On Thursday, June 9th, 14:10 CET, Chordates CEO Anders Weilandt will participate on an investment event hosted by Västra Hamnen Corporate Finance. He will present the latest developments in the company, such as the recently completed first phase of the marketing authorization process in the United States, the upcoming representative office in Saudi Arabia and the marketing efforts in the United Kingdom.

The event is a hybrid event that is held for an audience in Studio Malmö and livestreamed on Västra Hamnens Youtube channel.

Time: June 9th, 14:10 - 14:35
Registration for physical participation
Registration for online participation

A recording of the broadcast will be available afterwards on Chordates website and on the Västra Hamnen Corporate Finance YouTube channel.

About Västra Hamnen Corporate Finance
Västra Hamnen Corporate Finance is an independent advisor who assists companies and owners with, for example, raising capital and advising in connection with corporate transactions. The company currently employs 8 people and operates from Malmö. Västra Hamnen Corporate Finance is under the supervision of the Swedish Financial Supervisory Authority.

For more information, please contact:
Anders Weilandt, CEO
Cell: +46 733-874277
e-mail: anders.weilandt@chordate.com

About Chordate
Chordate Medical Holding AB (publ) is a medical technology company that for over ten years has developed, patented and CE-marked a new neuromodulation treatment technology for chronic nasal congestion (rhinitis) and chronic migraine. The company offers its product via distributors to clinics and hospitals in selected European markets, Israel, and Saudi Arabia. Chordate Medicals share is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH). Read more at www.chordate.com/en/

Chordates Certified Adviser on Nasdaq First North Growth Market Stockholm is Västra Hamnen Corporate Finance AB, +46 40 200 250, ca@vhcorp.se.

N.B. The English text is an in-house translation of the original Swedish text. Should there be any disparities between the Swedish and the English text, the Swedish text shall prevail.

Fler Nyheter

Press releases

If you want to read our press releases, there are available in the Investor Relations section or by clicking the link below.

Press releases

For questions about Chordate's share price or other investment-related topics, please see if the answer is here.

For questions about the medical effects of the K.O.S treatment, please see if the answer is here.

To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company's share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

 

Contact us

The information is handled according to our  privacy policy.